• Global headwinds including tariff wars, geopolitical instability, constrained health budgets, and tougher regulatory environments
• Revenues declined 25% year-on-year due to global market disruptions
• Optimised existing products and advanced development of new devices leveraging proprietary IP

Uscom Limited, a medical device company, has reported its preliminary financial results for the year ended 30 June 2025. The company experienced a 25% decline in revenues to $3.16 million, which it attributed to global headwinds including tariff wars, geopolitical instability, constrained health budgets, and tougher regulatory environments. The US saw a reduction in healthcare spending post-election, while Europe redirected healthcare spending toward military commitments amid the war in Ukraine. China also saw a 50% decline in sales due to tariff and trade restrictions. However, Southeast Asia continued to meet growth forecasts, providing some regional resilience. Prior to the COVID-19 pandemic, Uscom had enjoyed 10 consecutive years of 24% compound annual growth rate (CAGR). The pandemic's impact halved global revenues, but the company saw a 33% rebound in revenue growth in FY24. Unfortunately, FY25 revenues declined 25% year-on-year due to the ongoing global market disruptions. On the operational front, Uscom optimised its existing products to match market expectations, advanced the development of new devices leveraging its proprietary IP, achieved regulatory approvals for key products in major markets, and laid the foundation for new distributor partnerships and expanded global reach. Despite the challenging conditions, the company remains optimistic about its long-term prospects, noting that healthcare demand remains universal and resilient. Uscom believes it is well-positioned to return to its historical growth trajectory as global conditions stabilise, with FY25 serving as a year of resilience and preparation to capture growth opportunities during the recovery phase.

Uscom is well-positioned to return to its historical growth trajectory as global conditions stabilise. FY25 was a year of resilience and preparation -- strengthening product portfolio, regulatory footprint, and distribution networks to capture growth opportunities during recovery.